Pulsincap Designing of Rivaroxaban
BVP Deepthi, N Rachana Kumari, V Manisree, K Sandhya Rani, P Krishna and Dr. JVC Sharma
The purpose of the present study was to design and evaluate an oral, site specific, pulsatile drug delivery system containing Rivaroxaban as a model drug, which can be time dependent manner, to modulate the drug level in synchrony is a member of the drug class known as statins. It is used for lowering cholesterol based on chrono pharmaceutical considerations. The basic design consists of an insoluble hard gelatin capsule body, filled with powder blend and sealed with a hydrogel plug. The powder blend containing Rivaroxaban, sodium starch glycolate, cross carmellose sodium, microcrystalline cellulose and talc was prepared and evaluated for flow properties and FTIR studies. The prepared formulations were evaluated for drug content, weight variation and in vitro release studies. FTIR studies confirmed that there was no interaction between drug and polymers and in vitro release studies of pulsatile device revealed that increasing hydrophillic polymer content resulted in delayed release of Rivaroxaban from the pulsincap after a predetermined lag time of 6hrs. Based on in vitro studies performed, F8 was found to be optimized formulation.
How to cite this article:
BVP Deepthi, N Rachana Kumari, V Manisree, K Sandhya Rani, P Krishna, Dr. JVC Sharma. Pulsincap Designing of Rivaroxaban. Pharma Innovation 2020;9(3):408-420.